Feature | June 01, 2015

Peer-Reviewed Publication Shows Larger Capacity IABP Have Greater Hemodynamic Effect on Patients

Retrospective study examines 50 cc IABPs versus 40 cc IABPs in real-world practice

IABP, peer review, Maquet, Journal of Invasive Cardiology

June 1, 2015 — Maquet Getinge Group announced the publication of a manuscript describing the exploration of the hemodynamic effects of the newer, larger-capacity 50 cc intra-aortic balloon pumps (IABPs) versus 40 cc IABPs in real-world clinical practice. The paper, titled "Hemodynamic Effects of Standard Versus Larger-Capacity Intraaortic Balloon Counterpulsation Pumps," appears in the April 2015 volume of The Journal of Invasive Cardiology.

The study, led by Navin K. Kapur, M.D., assistant director of the Interventional Cardiology Center at Tufts Medical Center; investigator at Tufts Molecular Cardiology Research Institute; and assistant professor at Tufts University School of Medicine, was a retrospective examination of demographic, hemodynamic and laboratory data in 26 consecutive subjects treated with a 50 cc IABP. These patients were compared with 26 patients receiving a 40 cc IABP between 2012 and 2013. IABP tracings were analyzed within 24 hours of implantation in all patients. Pulmonary artery catheter data were available before and after IABP implantation in 20 subjects.

The study found that the larger-capacity 50 cc IABPs provides greater diastolic augmentation and systolic unloading compared with the 40 cc IABP. In the analysis, recipients of the 50 cc IABP were observed to achieve a greater reduction in cardiac filling pressures and increased cardiac output compared with the 40 cc group. It was also observed that a greater number of patients achieved a reduction in systolic pressure in the 50 cc IABP group compared with the 40 cc IABP group — the magnitude of systolic unloading correlates directly with the magnitude of diastolic augmentation and inversely with pulmonary artery occlusion pressure. Taken together, these observations suggest that the 50 cc IABP may achieve a greater hemodynamic effect compared with the standard 40 cc IABP.

"The intra-aortic balloon pump remains the most widely used form of mechanical hemodynamic support for cardiac patients because of their clinical efficacy and safety profile across a broad range of patient care scenarios," said Marc Cohen, chief of the Division of Cardiology at Newark Beth Israel Medical Center, Newark, New Jersey, and professor of medicine at Rutgers-New Jersey Medical School. "Given IABPs' continuing role in the management of high-risk patients with and without cardiogenic shock, new research into the newer 50 cc balloon is key to better understanding the role of IABPs in the modern era of acute cardiovascular care. The 50 cc IABP recipients demonstrated higher augmented diastolic blood pressure and greater systolic unloading compared to 40 cc IAB patients which is encouraging and warrants more research into whether this larger capacity balloon offers meaningful morbidity and mortality benefits."

For more information: www.invasivecardiology.com

Related Content

Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init